Clinical Trial Update: A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dose and pharmacodynamic efficacy of Sialic Acid-Extended Release (SA-ER) tablets in patients with GNE myopathy or hereditary inclusion…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gne Myopathy
• Hereditary Inclusion Body Myopathy

Drugs mentioned

• SA-ER (Sialic Acid-Extended Release) tablets (sialic acid extended-release)

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: GNE Myopathy, Hereditary Inclusion Body Myopathy | Phase 2 | Status: COMPLETED